High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis

Results of a German study presented today at the International Liver Congress 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver .

Read the whole article on Physorg

More from Physorg